Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 452 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Banner Children's at Desert — Mesa, Arizona
+ 182 more sites in the U.S.
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Locations: - City of Hope Phoenix — Goodyear, Arizona
- Mayo Clinic - Phoenix — Phoenix, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- Cancer Treatment Center of America Phoenix — Goodyear, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
+ 47 more sites in the U.S.
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Locations: - Phoenix Children's Hospital — Phoenix, Arizona
- Arkansas Children's Hospital — Little Rock, Arkansas
- MemorialCare Miller Children's and Women's Hospital Long Beach — Long Beach, California
+ 42 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona
+ 40 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Locations: - Mayo Clinic Phoenix — Phoenix, Arizona
- Kaiser Permanente Southern California — Irvine, California
- University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Locations: - Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
- Southern VA Health Care System /ID# 266254 — Tucson, Arizona
- UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Locations: - City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Locations: - St Bernards Medical Center — Jonesboro, Arkansas
- UCLA Department of Medicine Hematologyoncology — Los Angeles, California
- Pih Health Whittier Hospital — Whittier, California
+ 18 more sites in the U.S.
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Locations: - Quetzal Site 1 — Duarte, California
- Quetzal Site 5 — Stanford, California
- Quetzal Site 4 — Buffalo, New York
+ 3 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Locations: - Study Site 102 — St. Petersburg, Florida
- Study Site 101 — Fort Wayne, Indiana
- Study Site 105 — Westbrook, Maine
+ 2 more sites in the U.S.